- Trials with a EudraCT protocol (148)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
148 result(s) found for: pH value.
Displaying page 1 of 8.
EudraCT Number: 2017-002067-18 | Sponsor Protocol Number: B12CS-B13CS | Start Date*: 2018-12-11 | |||||||||||
Sponsor Name:Advicenne | |||||||||||||
Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses... | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000539-42 | Sponsor Protocol Number: RB2-NL-1518 | Start Date*: 2016-04-15 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th... | ||
Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017351-96 | Sponsor Protocol Number: baclofen2009 | Start Date*: 2009-12-23 |
Sponsor Name:UZleuven | ||
Full Title: A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI response | ||
Medical condition: Gastroesophageal reflux disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000298-22 | Sponsor Protocol Number: PRENECAL | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial. St... | |||||||||||||
Medical condition: incidence of nephrocalcinosis in extremely preterm infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004174-34 | Sponsor Protocol Number: Citalopram2017 | Start Date*: 2018-04-10 |
Sponsor Name:Targid, KU Leuven | ||
Full Title: A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response | ||
Medical condition: Functional heartburn and reflux hypersensitivity with incomplete respons to proton pomp inhibitors | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002068-42 | Sponsor Protocol Number: B14CS | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Advicenne | |||||||||||||
Full Title: Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000142-22 | Sponsor Protocol Number: 148-2016 | Start Date*: 2017-05-24 | |||||||||||
Sponsor Name:Helm AG | |||||||||||||
Full Title: Assessment of therapeutical equivalence of a newly developed vaginal tablet containing 10 μg of estradiol in comparison with a marketed reference product (Vagifem®) – a double-blind, double-dummy, ... | |||||||||||||
Medical condition: Investigation of efficacy, safety and tolerability of estradiol vaginal tablets in postmenopausal women with vaginal atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000618-20 | Sponsor Protocol Number: 40084-22084 | Start Date*: 2012-11-05 | |||||||||||
Sponsor Name:European Organization for the Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA | |||||||||||||
Medical condition: Patients with resected head of pancreas adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002104-40 | Sponsor Protocol Number: BAY63-2521/16097 | Start Date*: 2013-03-14 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in ... | |||||||||||||
Medical condition: Chronic Trombo Embolic Pulmonary Hypertention | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) PT (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) NL (Completed) IT (Completed) AT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003099-10 | Sponsor Protocol Number: DCR-PHXC-301 | Start Date*: 2019-06-12 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals Inc | |||||||||||||
Full Title: An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria | |||||||||||||
Medical condition: Primary Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PL (Completed) IT (Trial now transitioned) RO (Completed) NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003020-32 | Sponsor Protocol Number: A011-16 | Start Date*: 2022-02-03 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary ... | |||||||||||||
Medical condition: Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002223-32 | Sponsor Protocol Number: E2007-0507 | Start Date*: Information not available in EudraCT |
Sponsor Name:Charité Universitaetsmedizin | ||
Full Title: A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery. | ||
Medical condition: Cardiac surgical patients in whom the use of cardiopulmonary bypass is planned and having at least one ore more of the following risk factors for post-operative acute kidney injury • Age ≥ 70 years... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-006276-11 | Sponsor Protocol Number: VR496/005 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:Vectura Limited | |||||||||||||
Full Title: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cys... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002949-32 | Sponsor Protocol Number: SPHERE-HF | Start Date*: 2017-03-22 |
Sponsor Name:Fundació Clínic per la recerca Biomédica [...] | ||
Full Title: β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial | ||
Medical condition: Pulmonary Hypertension secondary to heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-004714-25 | Sponsor Protocol Number: REALIB-LLA-2017 | Start Date*: 2018-07-25 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients wi... | |||||||||||||
Medical condition: Acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002461-66 | Sponsor Protocol Number: CABL001A2301 | Start Date*: 2017-10-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyro... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Ongoing) BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) BE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003405-98 | Sponsor Protocol Number: dexFEMv2 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:ACCORD University of Edinburgh [...] | |||||||||||||
Full Title: Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding | |||||||||||||
Medical condition: Endometrial glucocorticoid deficiency in Heavy Menstrual Bleeding | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002216-40 | Sponsor Protocol Number: CML1516 | Start Date*: 2016-10-04 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS | |||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004887-74 | Sponsor Protocol Number: AC-065D301 | Start Date*: 2019-08-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | |||||||||||||
Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003276-39 | Sponsor Protocol Number: PR(AG)293/2019 | Start Date*: 2019-11-12 |
Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL | ||
Full Title: Liver impairment recovery related to parenteral nutrition with omega-3 fatty acids: randomized clinical trial. | ||
Medical condition: Critically ill adult patients with parenteral nutrition and liver parameters altered. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
